Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders
Launched by KANGBUK SAMSUNG HOSPITAL · Jan 8, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different factors affect the treatment and outcomes for people with anxiety disorders, specifically panic disorder. The researchers want to gather detailed information about patients' brain activity, behaviors, and other health conditions to better understand how anxiety works and how to treat it effectively. They will use advanced technologies like virtual reality (VR) to create realistic environments that can trigger anxiety symptoms, as well as brain scans (MRI) and brain wave measurements (EEG) to see how these symptoms are related to brain activity.
To be eligible for this study, participants should be adults aged 19 to 60 years. Those with anxiety disorders must be diagnosed by a qualified psychiatrist and able to understand and consent to the study. Healthy individuals who do not have any psychiatric symptoms can also participate. However, certain conditions, such as severe physical illnesses, history of seizures, or current substance abuse, would exclude someone from joining. Participants can expect to engage in VR activities and undergo brain scans, which will help researchers learn more about anxiety and improve treatment options in the future.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Anxiety Behavior Group
- • Adults aged 19-60 years.
- • Diagnosed with an anxiety disorder based on DSM-5 diagnostic criteria, evaluated by a board-certified psychiatrist.
- • Individuals who fully understand the study's purpose and process and provide informed consent.
- • 2. Healthy Control Group
- • Adults aged 19-60 years.
- • Individuals who report no psychiatric symptoms and are not taking any psychotropic medications.
- • Individuals who fully understand the study's purpose and process and provide informed consent.
- Exclusion Criteria:
- • 1. Anxiety Behavior Group
- • Individuals unable to read the consent form.
- • Individuals with difficulty using virtual reality devices.
- • Individuals with a history of epileptic seizures, brain injuries, or neurological disorders.
- • Individuals with severe physical illnesses (e.g., cancer, tuberculosis, severe cardiovascular diseases).
- • Individuals with substance or alcohol use disorders.
- • Individuals with pacemakers or implanted metallic devices.
- • Pregnant individuals or those in vulnerable environments, such as institutional employees.
- • 2. Healthy Control Group
- • Exclusion criteria for the Anxiety behavior group apply.
- • Additionally, individuals with any current or past psychiatric disorders are excluded.
About Kangbuk Samsung Hospital
Kangbuk Samsung Hospital is a leading healthcare institution in South Korea, renowned for its commitment to advanced medical research and clinical excellence. As a sponsor of clinical trials, the hospital integrates cutting-edge technology and innovative therapies to enhance patient care and outcomes. With a multidisciplinary team of experienced researchers and healthcare professionals, Kangbuk Samsung Hospital is dedicated to conducting rigorous clinical studies that adhere to the highest ethical standards. Its focus on translational medicine aims to bridge the gap between laboratory findings and clinical applications, ultimately contributing to the advancement of medical science and improving therapeutic options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Jongno Gu, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported